Leerink Partnrs Raises Earnings Estimates for XOMA Royalty

Key Points

• Leerink Partners has raised their FY2026 earnings per share (EPS) estimate for XOMA Royalty to $0.67, increasing from a prior estimate of $0.61, despite a current consensus estimate of (1.41) EPS.
• XOMA Royalty's stock has shown resilience, with recent trading reaching $31.87, and it has seen a significant market capitalization of $381.47 million.
• Insider activity includes CEO Owen Hughes selling 25,637 shares, reducing his ownership by 29.02% to approximately $1.59 million in stock value.

XOMA Royalty Corporation (NASDAQ:XOMA - Free Report) - Equities research analysts at Leerink Partnrs boosted their FY2026 earnings per share (EPS) estimates for XOMA Royalty in a report released on Thursday, August 14th. Leerink Partnrs analyst D. Risinger now expects that the biotechnology company will post earnings per share of $0.67 for the year, up from their previous forecast of $0.61. The consensus estimate for XOMA Royalty's current full-year earnings is ($1.41) per share.

Several other equities analysts also recently issued reports on XOMA. HC Wainwright restated a "buy" rating and set a $104.00 price objective on shares of XOMA Royalty in a report on Wednesday, May 28th. Benchmark started coverage on XOMA Royalty in a report on Thursday, April 17th. They set a "buy" rating and a $35.00 price objective on the stock. Wall Street Zen upgraded XOMA Royalty from a "hold" rating to a "buy" rating in a report on Monday. Finally, Zacks Research raised XOMA Royalty to a "hold" rating in a research report on Tuesday.

XOMA Royalty Stock Performance

Shares of XOMA traded up $0.28 on Friday, reaching $31.87. The company's stock had a trading volume of 7,798 shares, compared to its average volume of 43,261. XOMA Royalty has a 12-month low of $18.35 and a 12-month high of $35.00. The company has a debt-to-equity ratio of 1.18, a current ratio of 5.54 and a quick ratio of 5.54. The stock has a market capitalization of $381.47 million, a P/E ratio of -20.45 and a beta of 1.00. The stock's 50 day simple moving average is $26.28 and its two-hundred day simple moving average is $24.31.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last posted its earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 EPS for the quarter, topping the consensus estimate of ($0.12) by $0.60. XOMA Royalty had a positive return on equity of 2.54% and a negative net margin of 27.57%. The business had revenue of $13.13 million during the quarter, compared to analysts' expectations of $9.39 million.

Institutional Investors Weigh In On XOMA Royalty

Large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its holdings in shares of XOMA Royalty by 238.9% during the fourth quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company's stock valued at $318,000 after acquiring an additional 8,522 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of XOMA Royalty by 38.0% during the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company's stock valued at $113,000 after purchasing an additional 1,183 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of XOMA Royalty by 89.8% during the 4th quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company's stock worth $423,000 after buying an additional 7,619 shares in the last quarter. Barclays PLC grew its stake in XOMA Royalty by 13.6% in the fourth quarter. Barclays PLC now owns 12,784 shares of the biotechnology company's stock valued at $336,000 after purchasing an additional 1,528 shares during the last quarter. Finally, Eversept Partners LP boosted its holdings in XOMA Royalty by 1.2% in the fourth quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company's stock worth $2,508,000 after acquiring an additional 1,128 shares in the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Owen Hughes sold 25,637 shares of the company's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $25.38, for a total transaction of $650,667.06. Following the completion of the sale, the chief executive officer owned 62,701 shares of the company's stock, valued at approximately $1,591,351.38. This represents a 29.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 9.10% of the stock is currently owned by corporate insiders.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.